A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903

BACKGROUND: FLAURA, the prospective trial of osimertinib as a first-line therapy compared with first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), did not show superior survival benefit for osimertinib in either the subgroup of Asians or the subgroup with the L8...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, K., Morise, M., Wakuda, K., Hataji, O., Shimokawaji, T., Takahashi, K., Furuya, N., Takeyama, Y., Goto, Y., Abe, T., Kato, T., Ozone, S., Ikeda, S., Kogure, Y., Yokoyama, T., Kimura, M., Yoshioka, H., Murotani, K., Kondo, M., Saka, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134659/
https://www.ncbi.nlm.nih.gov/pubmed/33984681
http://dx.doi.org/10.1016/j.esmoop.2021.100115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134659/
https://www.ncbi.nlm.nih.gov/pubmed/33984681
http://dx.doi.org/10.1016/j.esmoop.2021.100115

Ejemplares similares